Establishment Labs Holdings Inc. (NASDAQ:ESTA) Q4 2022 Earnings Conference Call February 27, 2023 4:30 PM ET

Company Participants

Raj Denhoy - Chief Financial Officer

Juan Jose Chacon-Quiros - Chief Executive Officer

Conference Call Participants

Zach Weiner - Jefferies

Josh Jennings - Cowen

George Sellers - Stephens

Anthony Petrone - Mizuho Group

Neil Chatterji - B. Riley Securities

Sam Eiber - BTIG

Operator

Greetings, and welcome to the Establishment Labs Fourth Quarter 2022 Financial Results Conference Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions] Please note, this conference is being recorded.

I will now turn the conference over to our host, Raj Denhoy, Chief Financial Officer. Thank you. You may begin.

Raj Denhoy

Thank you, operator, and thank you everyone for joining us.

With me today is Juan Jose Chacon-Quiros, our Chief Executive Officer. Following our prepared remarks, we'll take your questions.

Before we begin, I would like to remind you that comments made by management during this call will include forward-looking statements from the meaning of federal securities laws. These include statements on Establishment Labs' financial outlook and the company's plan to timing for product development and sales.

These forward-looking statements are based on management's current expectations and involve risks and uncertainties. For a discussion of the principal risk factors and uncertainties that may affect our performance or cause actual results to differ materially from these statements, I encourage you to review our most recent annual and quarterly reports on Form 10-K and Form 10-Q as well as other SEC filings, which are available on our website at establishmentlabs.com.

I'd also like to remind you that our comments will include certain non-GAAP financial measures with respect to our performance, including but not limited to sales results, which can be stated on a constant currency basis. Reconciliations to the most directly comparable GAAP financial measures can be found in today's press release, which is available on our website.

Please also note that Establishment Labs received an investigational device exemption from the FDA for Motiva Implants and is undergoing a clinical trial to support regulatory approval in the United States. We continually seek to expand the geographies in which our products are regulatory approved. Please check with your local authorities for specific product availability.

The content of this conference call contains time sensitive information, accurate only as of the date of this live broadcast February 27, 2023. Except as required by law, Establishment Labs undertakes no obligation to revise or otherwise update any statement to reflect events or circumstances after the date of this call.